TL;DR — Key Takeaways
6-in-1 detection: Influenza A + Influenza B + COVID-19 + HMPV + RSV + Adenovirus in a single cassette, results in 10–15 minutes.
HMPV differentiation: Only the 6-in-1 panel distinguishes HMPV from RSV — critical for targeted pediatric and elderly care.
Certifications: CE certified, ISO 13485, MDSAP, TGA (Australia) approved.
When a child arrives at an urgent care clinic with wheezing and fever, the differential diagnosis spans influenza, COVID-19, RSV, and — increasingly — Human Metapneumovirus (HMPV). These pathogens share enough clinical features that symptom-based diagnosis is unreliable. Yet the treatment path differs depending on which virus is responsible. Because the 6-in-1 combo test panel detects six respiratory pathogens simultaneously from a single nasal swab, it collapses what would otherwise require three or four separate rapid tests into one cassette with results in 10–15 minutes. For clinic networks managing patient throughput, this is both a clinical and operational advantage.
In this guide, I’ll walk through the clinical rationale for the 6-in-1 panel, how HMPV fits into the respiratory pathogen landscape alongside RSV and influenza, and how clinic networks are using the 6-in-1 combo test to improve diagnostic speed and treatment targeting.
The Clinical Case for a 6-Pathogen Panel
The respiratory pathogen landscape has become more complex since the COVID-19 pandemic accelerated multiplex testing adoption. Before 2020, most clinic networks used single or 3-pathogen rapid tests. The experience of managing multiple respiratory threats simultaneously exposed the diagnostic gap — a patient presenting with influenza-like illness could test negative on an influenza rapid test and still have COVID-19, RSV, or HMPV. Because each of these pathogens requires a different clinical response — oseltamivir for influenza, monoclonal antibodies for high-risk COVID-19 patients, supportive care for RSV — accurate differentiation directly drives treatment decisions.
The 6-in-1 panel eliminates this diagnostic ambiguity. A single nasal swab tested on the combo cassette produces individual results for all six pathogens, allowing the clinician to read the test lines and immediately understand which pathogen — or combination of pathogens — is responsible for the patient’s presentation. For pediatric clinics and urgent care centers where 40–60% of patients present with influenza-like illness during respiratory season, the ability to run one test instead of three or four represents a significant improvement in diagnostic workflow efficiency.
Understanding HMPV: The Pathogen That’s Been Underdiagnosed
Human Metapneumovirus (HMPV) is a single-stranded RNA virus of the Paramyxoviridae family, first identified in 2001 in the Netherlands. Despite being one of the most common causes of upper respiratory infection worldwide — estimated to account for 4–8% of all respiratory infections in children under 5 — HMPV remains significantly underdiagnosed in clinical practice. Because HMPV symptoms closely mirror those of influenza and RSV, clinicians without access to specific HMPV testing often default to treating the patient as influenza or as an unknown viral respiratory infection.
This diagnostic gap has clinical consequences. HMPV infection in young children can progress to bronchiolitis or pneumonia, and in elderly patients and immunocompromised individuals, HMPV can cause severe lower respiratory tract disease requiring hospitalization. Because the 6-in-1 panel includes HMPV alongside the five other most clinically significant respiratory pathogens, it gives clinic networks the ability to identify HMPV infections specifically — rather than lumping them into a generic “viral respiratory infection” diagnosis that doesn’t guide treatment.
HMPV vs. RSV: Why the Distinction Matters Clinically
I want to address this directly, because it’s the question I’m asked most frequently by clinic network buyers evaluating the 6-in-1 panel: “Can’t RSV and HMPV just be treated the same way?” The answer is no — not entirely. While both pathogens cause similar clinical syndromes and both peak during winter respiratory seasons, there are meaningful differences in epidemiology, patient groups at highest risk, and clinical management implications.
RSV epidemiology: RSV is the leading cause of bronchiolitis in infants under 12 months and a major cause of pneumonia in children under 2 years. It also causes significant disease burden in adults over 65, particularly those with chronic cardiopulmonary disease. RSV seasonality typically peaks in winter months (December–February in the Northern Hemisphere), with a secondary smaller peak in spring.
HMPV epidemiology: HMPV has two peak seasons — late winter/early spring (similar to RSV) and again in early summer in some regions. The clinical presentation of HMPV in children is similar to RSV: upper respiratory symptoms that may progress to lower respiratory involvement. However, HMPV has a somewhat longer incubation period (3–6 days vs. 1–3 days for RSV), and co-infection with other respiratory pathogens — including RSV — is documented in 10–15% of HMPV cases, which can complicate the clinical picture.
The treatment difference: Both RSV and HMPV are managed primarily with supportive care — hydration, fever management, oxygen supplementation for hypoxic patients. However, the specific clinical risk profiles differ. RSV disproportionately affects infants under 6 months, while HMPV causes more severe disease in children aged 1–3 years and in immunocompromised adults. Identifying which pathogen is responsible — rather than treating both as “viral bronchiolitis” — matters for cohorting decisions in hospital settings, for parental counseling about expected disease duration, and for monitoring high-risk patients appropriately.
Influenza A/B + COVID-19: The Established Respiratory Threat Pair
Influenza A and Influenza B remain the most clinically significant causes of seasonal respiratory infection globally, responsible for 3–5 million severe cases and 290,000–650,000 deaths annually according to WHO data. Because oseltamivir (Tamiflu) and baloxavir marboxil (Xofluza) are most effective when administered within 48 hours of symptom onset, rapid and accurate influenza diagnosis directly enables antiviral treatment. COVID-19, while less prevalent as an endemic seasonal pathogen, continues to circulate and requires differentiated management — particularly for high-risk patients who may benefit from Paxlovid or other antiviral therapy.
The 6-in-1 panel detects Influenza A, Influenza B, and SARS-CoV-2 on three separate test lines, allowing the clinician to distinguish between these pathogens without running additional tests. In markets where influenza vaccination programs are in place, a negative influenza result on the 6-in-1 panel helps confirm that a patient’s respiratory symptoms are due to another pathogen — reducing unnecessary antibiotic prescriptions for viral illness and enabling targeted COVID-19 management.
Adenovirus: The Less-Discussed Respiratory Pathogen
Adenovirus is a double-stranded DNA virus with over 100 known serotypes, approximately 50 of which cause human infection across respiratory, ocular, gastrointestinal, and urinary tracts. In the respiratory context, adenovirus serotypes 3, 4, 7, 14, and 21 are most commonly associated with acute respiratory disease. Adenovirus respiratory infections are characterized by longer duration of fever compared to influenza, higher rates of conjunctivitis co-infection, and — in military recruit settings — documented outbreaks of febrile respiratory illness requiring cohort isolation.
For clinic networks, adenovirus identification on the 6-in-1 panel serves two purposes: first, it enables appropriate counseling about illness duration and transmission prevention (adenovirus is transmissible via fomites and swimming pools, not just respiratory droplets); second, it provides epidemiological surveillance value for public health officials tracking respiratory pathogen circulation patterns.
Specimen Collection and Test Procedure
The 6-in-1 combo test uses a nasal swab specimen — either a standard nasal swab or a nasopharyngeal swab, depending on the clinical protocol in use at your clinic. Because nasal swab collection is less invasive than nasopharyngeal swab and can be performed by trained clinic staff or the patient themselves under supervision, it reduces patient discomfort and improves compliance with repeat testing. This is particularly relevant for pediatric clinic networks where nasopharyngeal swab resistance is a significant operational challenge.
The test procedure follows the standard lateral flow format: the swab is placed in the extraction buffer, the buffer is applied to the cassette sample well, and results are read at 10–15 minutes. Six visible test lines appear corresponding to Flu A, Flu B, COVID-19, HMPV, RSV, and Adenovirus, plus a control line that confirms the test has run correctly. Because the 6-in-1 panel requires only a single specimen collection and produces six individual results, the per-pathogen cost is significantly lower than running six separate single-plex tests.
Certifications and Regulatory Compliance
The 6-in-1 combo test cassette is manufactured under ISO 13485 and MDSAP quality management systems. It carries CE marking for professional-use IVD distribution in European markets and has received Australian TGA approval (ARTG ID: 525693). Because regulatory requirements vary by destination market, clinic networks importing the 6-in-1 panel should confirm the specific registration status for their country before placing large orders. The Australian TGA listing demonstrates a validated quality management system and clinical performance data package that facilitates registration in other regulated markets.
Private-Label and OEM Options
For large clinic networks and healthcare organizations operating under their own branded diagnostic product lines, the 6-in-1 combo test is available for private-label customization. Customization options include:
Custom packaging in destination market language with local regulatory language
Branded outer retail packaging with clinic network or healthcare system logos
Customized instructions for use and clinical decision-support insert cards
Customized cassette design (subject to technical feasibility review and volume requirements)
Private-label production for the 6-in-1 combo cassette requires 8–12 weeks for initial production and quality validation. I recommend building a 12-week buffer into your inventory transition planning when switching from a standard supplier brand to private-label product.
Evaluating a Wholesale Supplier for the 6-in-1 Panel
When evaluating suppliers for the 6-in-1 combo test, clinic network procurement managers should verify:
HMPV line performance data: The inclusion of HMPV in the panel is the defining feature — verify that the HMPV line has been independently validated with a sensitivity and specificity of at least 85% against a molecular reference method (PCR). Some cheaper combo tests have poor HMPV line performance that compromises the clinical value of the panel.
Cross-reactivity data: Confirm that the supplier has published cross-reactivity validation data showing the test does not produce false positives when testing specimens containing high concentrations of non-target respiratory pathogens (rhinovirus, coronavirus OC43/NL63, etc.).
Current regulatory registration: Verify CE marking and TGA listing documents directly — confirm the product name and catalog number match what you’re ordering. Some suppliers list a product but sell a different formulation.
Batch-to-batch consistency: Request performance data from at least three recent production batches to assess the consistency of the HMPV and RSV lines, which tend to have the greatest batch-to-batch variation in multiplex antigen tests.
About the Author: Angela Qin
Angela Qin is International Sales Director at Testsealabs (Hangzhou Testsea Biotechnology Co., Ltd.), a manufacturer of rapid diagnostic test kits including the FLU A/B + COVID-19 + HMPV + RSV + Adeno 6-in-1 combo test cassette. With hands-on experience supporting clinic network procurement and distribution across Asia, Europe, and North America, she specializes in multiplex respiratory panel diagnostics and OEM customization for healthcare networks.
Connect: Facebook
Frequently Asked Questions
What pathogens does the 6-in-1 combo test detect?
The 6-in-1 combo test detects six respiratory pathogens simultaneously: Influenza A, Influenza B, SARS-CoV-2 (COVID-19), Human Metapneumovirus (HMPV), Respiratory Syncytial Virus (RSV), and Adenovirus (Adeno). The test uses a lateral flow immunochromatographic assay and delivers results in 10–15 minutes from a single nasal swab.
How does HMPV differ clinically from RSV?
HMPV and RSV both cause respiratory infections with overlapping symptoms — cough, fever, wheezing, and difficulty breathing — particularly in young children and elderly patients. However, HMPV tends to present with upper respiratory symptoms (rhinorrhea, sore throat) that can progress to lower respiratory involvement. RSV is more commonly associated with bronchiolitis in infants. The 6-in-1 combo test differentiates both, enabling targeted treatment decisions rather than symptomatic guesswork.
What clinical settings benefit most from the 6-in-1 panel?
The 6-in-1 panel is most valuable in urgent care clinics, pediatric practices, emergency departments, and senior care facilities where differential diagnosis of respiratory pathogens directly drives treatment decisions. In these settings, knowing whether a patient has HMPV versus RSV versus influenza versus COVID-19 determines whether antivirals, antibiotics, or supportive care is appropriate.
What certifications does the 6-in-1 combo test carry?
The 6-in-1 combo test cassette is certified to CE and manufactured under ISO 13485 and MDSAP quality management systems. It has received TGA approval for the Australian market (ARTG ID listed). Distributors should verify specific market authorization requirements for their destination country.
A/B + COVID-19 + HMPV + RSV + Adeno 6-in-1 Combo Test Cassette | Contact for wholesale pricing
Post time: Jun-04-2026